Restricted accessReview articleFirst published online 2025-06
Health Care Workers’ Attitudes Toward and Knowledge of the Clinical Application of Classic Psychedelics for People with Serious Illness: A Systematic Review
Recent research indicates that psychedelic-assisted therapy (PAT) may be a safe and effective treatment for several psychiatric disorders, including those experienced by people with serious physical illness. Understanding health care workers’ (HCWs’) attitudes and knowledge about the clinical application of psychedelics for patients with serious illness is important in progressing research and identifying factors to consider in potential future implementation of PAT.
Aim:
The aim of this systematic review was to synthesize quantitative, qualitative, and mixed methods studies that explored HCWs’ attitudes and knowledge about the role of psychedelics in treating psychological distress in patients with serious illness.
Design:
MEDLINE, PsycInfo, and CINAHL were searched for quantitative, qualitative, or mixed methods primary empirical studies, published in English from 2006 onward. Two reviewers independently screened articles for inclusion. The Joanna Briggs Institute (JBI) convergent approach to mixed methods systematic reviews guided synthesis of the findings of included studies. One reviewer extracted data from included studies which was checked for accuracy by another reviewer. Two reviewers independently critically appraised included studies using JBI critical appraisal tools.
Results:
The review included nine studies (seven qualitative, two quantitative) conducted in four countries. Five themes were developed: Polarized views about PAT for patients with serious illness; attitudes often informed by PAT research knowledge and heuristic methods; stronger evidence base needed to increase HCWs’ confidence and support implementation of PAT; barriers may hinder PAT’s potential integration into existing care models; and team-based approach and clinical education are essential to facilitate PAT.
Conclusion:
Although support for PAT varied, most HCWs perceived potential benefits in treating refractory distress, desired education about PAT, and called for further research to develop a stronger evidence base. Limitations of the review and included studies are discussed, along with implications of the findings and recommendations for future research.
Get full access to this article
View all access options for this article.
References
1.
KelleyAS, Bollens-LundE. Identifying the population with serious illness: The “denominator” challenge. J Palliat Med, 2018; 21(S2):S7–S16; doi: 10.1089/jpm.2017.0548
2.
BostonP, BruceA, SchreiberR. Existential suffering in the palliative care setting: An integrated literature review. J Pain Symptom Manage, 2011; 41(3):604–618; doi: 10.1016/j.jpainsymman.2010.05.010
3.
LeMayK, WilsonKG. Treatment of existential distress in life threatening illness: A review of manualized interventions. Clin Psychol Rev, 2008; 28(3):472–493; doi: 10.1016/j.cpr.2007.07.013
4.
OstuzziG, MatchamF, DauchyS, et al.Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev, 2018; 4(4):CD011006; doi: 10.1002/14651858.CD011006.pub3
5.
SaltS, MulvaneyCA, PrestonNJ. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database Syst Rev, 2017; 5(5):CD004596; doi: 10.1002/14651858.CD004596.pub3
6.
BauereißN, ObermaierS, OzunalSE, BaumeisterH. Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: Systematic review and meta-analysis of randomized controlled trials. Psychooncology, 2018; 27(11):2531–2545; doi: 10.1002/pon.4829
PhiferB. A review of the research and theological implications of the use of psychedelic drugs with terminal cancer patients. J Drug Issues, 1977; 7(3):287–292; doi: 10.1177/002204267700700308
9.
KastEC, CollinsVJ. Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg, 1964; 43:285–291.
10.
KastE. Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatr Q, 1967; 41(4):646–657; doi: 10.1007/BF01575629
11.
RossS. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry, 2018; 30(4):317–330; doi: 10.1080/09540261.2018.1482261
12.
LeeMA, ShlainB. Acid dreams: the complete social history of LSD, the CIA, the sixties and beyond (Rev ed).. Pan: London; 2001.
13.
RossS, AgrawalM, GriffithsRR, et al.Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. Neuropharmacology, 2022; 216:109174; doi: 10.1016/j.neuropharm.2022.109174
14.
GriffithsRR, JohnsonMW, CarducciMA, et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197; doi: 10.1177/0269881116675513
15.
RossS, BossisA, GussJ, et al.Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol, 2016; 30(12):1165–1180; doi: 10.1177/0269881116675512
16.
Agin-LiebesGI, MaloneT, YalchMM, et al.Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol, 2020; 34(2):155–166; doi: 10.1177/0269881119897615
17.
BarrettFS, JohnsonMW, GriffithsRR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol, 2015; 29(11):1182–1190; doi: 10.1177/0269881115609019
18.
VargasAS, LuisA, BarrosoM, et al.Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases—A systematic review and meta-analysis of clinical trials. Biomedicines, 2020; 8(9); doi: 10.3390/biomedicines8090331
19.
SchimmersN, BreeksemaJJ, Smith-ApeldoornSY, et al.Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: A systematic review. Psychopharmacology (Berl), 2022; 239(1):15–33; doi: 10.1007/s00213-021-06027-y
SholevarR, PeteetJ, SandersJ, BeaussantY. Disruption as an opportunity or threat: A qualitative analysis of factors influencing the attitudes of experts in serious illness care toward psychedelic-assisted therapies. Palliat Support Care, 2023; 1–6; doi: 10.1017/S1478951523001475
22.
RobertsonK. Psychedelic therapy is having a moment—here’s what you need to know. 2021.
23.
PlourdeL, ChangSL, FarzinH, et al.P3A Study Group. Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey. Palliat Med, 2024; 38(2):272–278; doi: 10.1177/02692163231222430
24.
WellsA, FernandesM, ReynoldsLM. Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review. Jps, 2024; 8(1):43–62; doi: 10.1556/2054.2023.00294
25.
Australian Government. Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists [press release]. Australian Government: Canberra; 2023.
26.
Research. CfDEa. Psychedelic drugs: Considerations for clinical investigations [Guidance document draft]. U.S. Food and Drug Administration: Rockville, M.D; 2023.
27.
MoullinJC, DicksonKS, StadnickNA, et al.Ten recommendations for using implementation frameworks in research and practice. Implement Sci Commun, 2020; 1:42; doi: 10.1186/s43058-020-00023-7
28.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021; 372:n71; doi: 10.1136/bmj.n71
29.
Veritas Health Innovation. Covidence systematic review software. Veritas Health Innovation: Melbourne, Australia.
30.
BeaussantY, SandersJ, SagerZ, et al.Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: Expert clinicians’ and investigators’ perspectives. J Palliat Med, 2020; 23(10):1323–1334; doi: 10.1089/jpm.2019.0603
31.
BeaussantY, TulskyJ, GuerinB, et al.Radcliffe Institute for Advanced Study Working Group on Psychedelic Research in Serious Illness. Mapping an agenda for psychedelic-assisted therapy research in patients with serious illness. J Palliat Med, 2021; 24(11):1657–1666; doi: 10.1089/jpm.2020.0764
32.
DavisAK, Agin-LiebesG, EspanaM, et al.Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J Psychoactive Drugs, 2022; 54(4):309–318; doi: 10.1080/02791072.2021.1971343
33.
EllowJM. Clinical social workers and psychedelic-assisted therapies: A qualitative study on knowledge, attitudes, and professional response. ProQuest Information & Learning, 2022.
34.
MayerCE, LeBaronVT, AcquavivaKD. Exploring the use of psilocybin therapy for existential distress: A qualitative study of palliative care provider perceptions. J Psychoactive Drugs, 2022; 54(1):81–92; doi: 10.1080/02791072.2021.1916659
35.
NilesH, FoggC, KelmendiB, LazenbyM. Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliat Care, 2021; 20(1):191; doi: 10.1186/s12904-021-00889-x
36.
ReynoldsLM, AkroydA, SundramF, et al.Cancer healthcare workers’ perceptions toward psychedelic-assisted therapy: A preliminary investigation. Int J Environ Res Public Health, 2021; 18(15); doi: 10.3390/ijerph18158160
37.
ReynoldsLM, BarnettB, WeleffJ, et al.The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. Pall Supp Care, 2024; 22(4):664–673; doi: 10.1017/S1478951522001481
38.
WinklerP, CsemyL. Self-experimentations with psychedelics among mental health professionals: LSD in the former Czechoslovakia. J Psychoactive Drugs, 2014; 46(1):11–19; doi: 10.1080/02791072.2013.873158
39.
SternC, LizarondoL, CarrierJ, et al.Methodological guidance for the conduct of mixed methods systematic reviews. JBI Evid Synth, 2020; 18(10):2108–2118; doi: 10.11124/JBISRIR-D-19-00169
ThomasJ, HardenA. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol, 2008; 8:45; doi: 10.1186/1471-2288-8-45
42.
Institute JB. Checklist for analytical cross sectional studies: Critical appraisal tools for use in JBI systematic reviews. Joanna Briggs Institute: Adelaide; 2020.
43.
Institute JB. The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews checklist for qualitative research. Joanna Briggs Institute: Adelaide, Australia; 2017.
44.
Abo ZiadR, GrynbaumMB, RoniP, Treister-GoltzmanY. The attitudes and beliefs of family physicians regarding the use of medical cannabis, knowledge of side effects, and barriers to use: A comparison between residents and specialists. Am J Ther, 2022; 29(4):e400–e409; doi: 10.1097/MJT.0000000000001236
45.
KondradE, ReidA. Colorado family physicians’ attitudes toward medical marijuana. J Am Board Fam Med, 2013; 26(1):52–60; doi: 10.3122/jabfm.2013.01.120089
46.
ZolotovY, VulfsonsS, ZarhinD, SznitmanS. Medical cannabis: An oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy, 2018; 57:4–10; doi: 10.1016/j.drugpo.2018.03.025
47.
GardinerKM, SingletonJA, SheridanJ, et al.Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis—A systematic review. PLoS One, 2019; 14(5):e0216556; doi: 10.1371/journal.pone.0216556
48.
BarnettBS, SiuWO, PopeHG.Jr., A survey of American psychiatrists’ attitudes toward classic hallucinogens. J Nerv Ment Dis, 2018; 206(6):476–480; doi: 10.1097/NMD.0000000000000828
49.
MeyerTD, MeirP, LexC, SoaresJC. Magic mushrooms—an exploratory look at how mental health professionals feel and think about psilocybin. Psychiatry Res, 2022; 316:114727; doi: 10.1016/j.psychres.2022.114727
50.
BarnettBS, BeaussantY, KingF, DoblinR. Psychedelic knowledge and opinions in psychiatrists at two professional conferences: An exploratory survey. J Psychoactive Drugs, 2022; 54(3):269–277; doi: 10.1080/02791072.2021.1957183
51.
RuckerJJ. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. Bmj, 2015; 350:h2902; doi: 10.1136/bmj.h2902
52.
MarseilleE, BertozziS, KahnJG. The economics of psychedelic-assisted therapies: A research agenda. Front Psychiatry, 2022; 13:1025726; doi: 10.3389/fpsyt.2022.1025726
TropeA, AndersonBT, HookerAR, et al.Psychedelic-assisted group therapy: A systematic review. J Psychoactive Drugs, 2019; 51(2):174–188; doi: 10.1080/02791072.2019.1593559
55.
PhelpsJ. Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology, 2017; 57(5):450–487; doi: 10.1177/0022167817711304
56.
HoloydaB. Psychedelic psychiatry: Preparing for novel treatments involving altered states of consciousness. Psychiatr Serv, 2020; 71(12):1297–1299; doi: 10.1176/appi.ps.202000213
57.
KittoSC, ChestersJ, GrbichC. Criteria for authors in the submission and assessment of qualitative research articles for the Medical Journal of Australia. Med J Australia, 2008; 188(4):243–246; doi: 10.5694/j.1326-5377.2008.tb01595.x
58.
O’CallaghanC, DwyerJ, SchofieldP. Thematic analysis informed by grounded theory (TAG) in healthcare research: Foundations and applications. Qual Res Psychol, 2024; 21(3):279–306; doi: 10.1080/14780887.2024.2347580
59.
NielsonEM, GussJ. The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies, 2018; 2(2):64–73; doi: 10.1556/2054.2018.009
60.
RichardsWA. Sacred knowledge: Psychedelics and religious experience. Columbia University Press: 2015.
61.
KaelenM, GiribaldiB, RaineJ, et al.The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berl), 2018; 235(2):505–519.
62.
O’CallaghanC, HubikDJ, DwyerJ, et al.Experience of music used with psychedelic therapy: A rapid review and implications. J Music Ther, 2020; 57(3):282–314; doi: 10.1093/jmt/thaa006
63.
MessellC, SummerL, BondeLO, et al.Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. Front Psychol, 2022; 13:873455; doi: 10.3389/fpsyg.2022.873455
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
